Targets › NCAM1
2 programs from 2 companies in 2 trials: 2 Phase 1; Neurology, Oncology; next expected readout Oct 2028.
This protein is a cell adhesion molecule involved in neuron-neuron adhesion, neurite fasciculation, outgrowth of neurites, etc.; FUNCTION: (Microbial infection) Acts as a receptor for rabies virus..; FUNCTION: (Microbial infection) Acts as a receptor for Zika virus. (UniProt, P13591)
Open in Phaseline: the race on NCAM1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| S.Biomedics | PSA-NCAM(+) NPC (neural precursor cells derived from human embryonic stem cell l Neural precursor cell transplantation therapy | NCAM1 | Phase 1 | Spinal Cord Injury, Acute | Oct 2028 |
| Masonic Cancer Center, University of Minnesota | AdaptNK Allogeneic KIR-HLA mismatched NK cell infusion enriched for CMV-induced adaptive NK cells | NCAM1, NKG2C | Phase 1 | Relapsed Adult AML | Mar 2030 |
Spinal Cord Injury, Acute (1) Relapsed Adult AML (1)
other (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.